RxDoctor Payments Data

Brian Inouye, MD

Urology · Albany, NYNPI 1467871178

Payments from drug & device makers

$56,966in general payments, 2019–2025

Across 64 payments — averaging $890.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$53K
  • Uromedica, Incorporated$2K
  • Laborie Medical Technologies Corp.$923
  • Coloplast$369
  • Johnson & Johnson$210
  • Astellas Pharma US Inc$200
  • plus $280 from 8 others

What the payments were for

  • Consulting fees$8001%
  • Grants$52,00091%
  • Travel & lodging$1,5263%
  • Food & beverage$2,4414%
  • Education$2000%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific35$53,458
Uromedica, Incorporated1$1,526
Laborie Medical Technologies Corp.3$923
Coloplast10$369
Johnson & Johnson4$210
Astellas Pharma US Inc2$200
Baxter Healthcare1$108
Rochester Medical Corporation2$46
C. R. Bard, Inc. & Subsidiaries1$31
180 Medical, Inc.1$25
Rigicon,inc.1$23
Pfizer1$17
BD1$16
Integra Lifesciences Corporation1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,966 in reported general payments places this provider in the 85th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$87,987
Medicare patients
242
Services billed
798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron79$70,307
GemtesaVibegron16$15,797
Trospium Chloride ErTrospium Chloride12$1,476
Tamsulosin Hcl85$1,003
Finasteride62$929
Clobetasol EmollientClobetasol Propionate/Emoll18$731
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$590
Cephalexin18$325
Clobetasol Propionate11$279
Levofloxacin16$118
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim21$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$200$70,30779 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 952 urology providers in New York.

Other urology in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →